Trinity Capital is committing $35M in equipment financing to ApiJect Systems, a public-benefit medical technology company focused on prefilled, single-dose injection devices. Based in Stamford, CT, ApiJect works with pharmaceutical companies to design rapidly scalable, cost-efficient drug delivery systems, and then assists in manufacturing those devices. The new facility from Trinity aims to allow ApiJect to maximize the value of their hard assets to continue to scale operations and fund growth initiatives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIN:
- Trinity Capital price target raised to $15.50 from $15 at Compass Point
- Trinity Capital Q2 Earnings Overview in Conference Call
- Trinity Capital Inc. Reports Second Quarter 2024 Financial Results
- Trinity Capital reports Q2 EPS 51c, consensus 52c
- Trinity Capital Boosts Borrowing Capacity and Extends Maturity